Koch B D, Schonbrunn A
Endocrinology. 1984 May;114(5):1784-90. doi: 10.1210/endo-114-5-1784.
Somatostatin (SRIF) inhibits vasoactive intestinal peptide (VIP)-stimulated cAMP accumulation in the GH4C1 strain of rat pituitary tumor cells, and this effect is responsible for SRIF inhibition of VIP-stimulated hormone release. In this study we examined the interaction between the SRIF receptor and adenylate cyclase in GH4C1 cell membranes. Maximal concentrations of VIP (50 nM) increased membrane adenylate cyclase activity 4.2-fold; half-maximal stimulation was observed with 0.75 nM VIP. SRIF noncompetitively inhibited the stimulatory effect of VIP, but it did not alter basal adenylate cyclase activity. The relative potencies of SRIF and two SRIF analogs as inhibitors of VIP-stimulated adenylate cyclase activity in membranes and of VIP-stimulated cAMP accumulation in intact cells were similar. Furthermore, the concentration of SRIF that caused half-maximal inhibition of adenylate cyclase activity (ED50 = 2.3 nM) was close to the equilibrium dissociation constant for SRIF (Kd = 0.40 nM) measured in membrane preparations in the presence of GTP. Therefore, SRIF inhibition of adenylate cyclase appears to be receptor mediated. As with receptors known to regulate adenylate cyclase by interaction with a guanine nucleotide regulatory subunit, SRIF receptor binding was decreased in the presence of guanine nucleotides. Addition of GTP (150 microM) or the nonhydrolyzable GTP analog guanyl-5'-yl-imidodiphosphate (100 microM) decreased the specific binding of [125I-Tyr1]SRIF to 31% and 13% of the control value, respectively. This decrease in specific binding was due entirely to decreased receptor affinity for SRIF. GTP (150 microM) increased the equilibrium dissociation constant for SRIF from 0.11 to 0.40 nM, whereas the number of binding sites was unaffected by the nucleotide (Bmax = 0.2 pmol/mg protein). Analysis of dissociation kinetics demonstrated that in the absence of guanyl nucleotides, the rate of [125I-Tyr1]SRIF dissociation was first order (t 1/2 = 180 min). However, in the presence of a half-maximal concentration of guanyl-5'-yl-imidodiphosphate (0.3 microM), [125I-Tyr1]SRIF dissociation occurred with biphasic kinetics. Fifty percent of the specifically bound peptide dissociated at the same rate as that observed in the absence of nucleotide, whereas the remainder dissociated 15 times more rapidly (t 1/2 = 9.6 min).(ABSTRACT TRUNCATED AT 400 WORDS)
生长抑素(SRIF)可抑制大鼠垂体肿瘤细胞系GH4C1中血管活性肠肽(VIP)刺激的环磷酸腺苷(cAMP)积累,且此效应是SRIF抑制VIP刺激的激素释放的原因。在本研究中,我们检测了GH4C1细胞膜中SRIF受体与腺苷酸环化酶之间的相互作用。VIP的最大浓度(50 nM)可使膜腺苷酸环化酶活性增加4.2倍;0.75 nM的VIP可观察到半数最大刺激作用。SRIF非竞争性抑制VIP的刺激作用,但不改变基础腺苷酸环化酶活性。SRIF及两种SRIF类似物作为膜中VIP刺激的腺苷酸环化酶活性抑制剂以及完整细胞中VIP刺激的cAMP积累抑制剂的相对效力相似。此外,导致腺苷酸环化酶活性半数最大抑制的SRIF浓度(ED50 = 2.3 nM)接近在存在鸟苷三磷酸(GTP)的膜制剂中测得的SRIF平衡解离常数(Kd = 0.40 nM)。因此,SRIF对腺苷酸环化酶的抑制似乎是受体介导的。与已知通过与鸟嘌呤核苷酸调节亚基相互作用来调节腺苷酸环化酶的受体一样,在存在鸟嘌呤核苷酸的情况下,SRIF受体结合减少。添加GTP(150 μM)或不可水解的GTP类似物鸟苷-5'-亚基-异亚丙基二磷酸(100 μM)分别使[125I-Tyr1]SRIF的特异性结合降低至对照值的31%和13%。特异性结合的这种降低完全是由于受体对SRIF的亲和力降低。GTP(150 μM)使SRIF的平衡解离常数从0.11 nM增加至0.40 nM,而结合位点的数量不受核苷酸影响(Bmax = 0.2 pmol/mg蛋白质)。解离动力学分析表明,在不存在鸟苷酸的情况下,[125I-Tyr1]SRIF的解离速率为一级(t1/2 = 180分钟)。然而,在存在半数最大浓度的鸟苷-5'-亚基-异亚丙基二磷酸(0.3 μM)的情况下,[125I-Tyr1]SRIF的解离呈现双相动力学。50%的特异性结合肽以与不存在核苷酸时观察到的相同速率解离,而其余部分解离速度快15倍(t1/2 = 9.6分钟)。(摘要截短于400字)